Cellular Immunotherapy—Highlights from TCT 2021

Ran Reshef, Pawel Muranski, Jeffrey S. Miller

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish (US)
Pages (from-to)527-532
Number of pages6
JournalTransplantation and Cellular Therapy
Volume27
Issue number7
Early online dateApr 26 2021
DOIs
StatePublished - Jul 1 2021

Bibliographical note

Funding Information:
Financial disclosure: R.R. reports consulting fees or honoraria from Gilead, Novartis, BMS, Bayer, Atara, TScan, CareDx, and Regeneron and clinical trial support to Columbia University from Gilead, BMS, Bluebird Bio, Janssen, Vertex, Atara, Immatics, Adaptimmune, Bellicum, Incyte, Takeda, Pharmacyclics, Tmunity, Shire, and Precision Biosciences. P.M. reports consulting fees from Atara and AstraZeneca. J.S.M. consults for and holds stock in Fate and GT BioPharma and receives research funds from these companies. These interests have been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policy. Financial disclosure: See Acknowledgments on page 531.

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Cite this